High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease

Published:2019-09-25 Issue:10 Volume:54 Page:1220-1225
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Bodini Giorgia¹,Demarzo Maria Giulia¹,Saracco Margherita¹,Coppo Claudia¹,De Maria Costanza¹,Baldissarro Isabella¹,Savarino Edoardo²,Savarino Vincenzo¹^ORCID,Giannini Edoardo G.¹^ORCID

Affiliation:

1. Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy;

2. Gastroenterolgy Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2019.1666914

Reference25 articles.

1. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

2. Review article: loss of response to anti-TNF treatments in Crohn’s disease

3. Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

4. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

5. Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immediate Hypersensitivity Reactions to Biologic Drugs in Children with Inflammatory Bowel Diseases;International Archives of Allergy and Immunology;2024-09-04

2. Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2023-12-10

3. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review;World Journal of Gastroenterology;2023-08-07

4. Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study;Journal of Clinical Medicine;2021-09-20

5. High anti-TNFα Concentrations Are Not Associated With More Adverse Events in Pediatric Inflammatory Bowel Disease;Journal of Pediatric Gastroenterology & Nutrition;2021-07-20